Antiviral combination plus standard therapy achieves ‘controlled biological state’ in HBV
LONDON — Therapy combining small interfering RNA, capsid assembly modulator and nucleotide analogue reduced HBsAg levels over 24 weeks compared with standard therapy, according to…